Published online Oct 16, 2025. doi: 10.12998/wjcc.v13.i29.111096
Revised: July 5, 2025
Accepted: August 13, 2025
Published online: October 16, 2025
Processing time: 66 Days and 16.8 Hours
Gestational diabetes mellitus (GDM) has emerged as a global public health cha
To synthesize current evidence on the pathophysiology, diagnosis, management, complications, and individualized treatment strategies of GDM.
We conducted a narrative review in accordance with PRISMA guidelines. Pub
GDM results from a complex interplay among progressive insulin resistance, β-cell dysfunction, immune dysregulation, and placental inflammation. Emerging evidence indicates that hyperglycemia before formal diagnosis can impair fetal programming via epigenetic mechanisms. GDM increases a mother’s risk of developing type 2 diabetes mellitus seven- to tenfold and raises the incidence of cardiovascular disease, preeclampsia, and cesarean delivery. Offspring are at higher risk of macrosomia, neonatal hypoglycemia, and future metabolic and cardiovascular disorders. Lifestyle modification remains the cornerstone of therapy and, when necessary, can be supplemented with pharmacologic agents such as metformin or insulin. Postpartum follow-up, breastfeeding support, and preconception counseling are vital to long-term metabolic health.
GDM requires precision-based, life-course care. Future priorities include early risk detection, biomarker validation, unified diagnosis, and culturally sensitive interventions to improve maternal-child outcomes.
Core Tip: This narrative review explores the latest evidence on gestational diabetes mellitus (GDM), emphasizing its pathophysiology, clinical management, and long-term cardiometabolic consequences. It highlights the role of early hyper